Title of article
Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial
Author/Authors
E Tauber، نويسنده , , H Kollaritsch، نويسنده , , M Korinek، نويسنده , , P Rendi-Wagner، نويسنده , , Bernd Jilma، نويسنده , , C Firbas، نويسنده , , S Schranz، نويسنده , , E Jong، نويسنده , , A Klingler، نويسنده , , S Dewasthaly، نويسنده , , CS Klade، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2008
Pages
7
From page
1847
To page
1853
Abstract
Background
Japanese encephalitis virus (JEV) is the leading cause of viral encephalitis in southeast Asia. Although no treatment is currently available, vaccination effectively prevents the disease. In a non-inferiority study, we aimed to compare the safe
Journal title
The Lancet
Serial Year
2008
Journal title
The Lancet
Record number
592192
Link To Document